MAPT and Alzheimer disease: As observed previously (27), the different AD-tau preparations showed nearly identical dose-dependent seeding profiles in the cortical neurons, and thus these separate preparations were pooled to provide a large AD-tau batch with activity comparable to the individual preparations (Fig. 1B) in sufficient quantity to support the compound screening effort.